中国癌症防治杂志2024，Vol.16Issue(4)：412-416,5.DOI:10.3969/j.issn.1674-5671.2024.04.05
达雷妥尤单抗联合苯达莫司汀治疗伴继发性髓外病变多发性骨髓瘤:单中心临床经验
Single-center clinical experience of daratumumab combined with bendamustine in the treatment of multiple myeloma patients with secondary extramedullary disease
摘要
Abstract
Objective To investigate the efficacy and safety of daratumumab combined with bendamustine in patients with relapsed/refractory multiple myeloma complicated by secondary extramedullary disease.Methods The clinical data of patients with relapsed/refractory multiple myeloma complicated by secondary extramedullary disease hospitalized in Guangxi Medical University Cancer Hospital from January 2021 to December 2023 were analyzed retrospectively.All patients had progressive disease on at least 3 prior treatment lines and followed by combination therapy with daratumumab and bendamustine.The efficacy and safety of the treatment were assessed based on the International Myeloma Working Group(IMWG)criteria and the National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 5.0.Results A total of 12 patients were included in the analysis,with 2 achieving complete response,4 achieving partial response,2 achieving minimal response,1 achieving stable disease,and 3 experiencing progressive disease.The overall response rate was 50％,and the median progression-free survival was 8 months.All patients experienced hematological toxicity,4 of which were grade Ⅲ-Ⅳ.Additionally,3 patients developed pneumonia during treatment,no treatment-related deaths occurred.Conclusions The combination of daratumumab and bendamustine demonstrates effectiveness in treating relapsed/refractory multiple myeloma complicated by secondary extramedullary disease,with manageable toxicities.This result deserves further investigation with a larger patient population.关键词
多发性骨髓瘤/复发/难治性/继发性髓外病变/达雷妥尤单抗/苯达莫司汀Key words
Multiple myeloma/Relapsed/refractory/Secondary extramedullary disease/Daratumumab/Bendamustine分类
医药卫生引用本文复制引用
周达,王明月,李喆,柯晴,岑洪..达雷妥尤单抗联合苯达莫司汀治疗伴继发性髓外病变多发性骨髓瘤:单中心临床经验[J].中国癌症防治杂志,2024,16(4):412-416,5.基金项目
广西自然科学基金区域高发疾病研究联合专项资助(2023GXNSFDA026019) （2023GXNSFDA026019）
